What is CODX's market cap?

$3.19M, based on the Nov 4 close of $0.36.

Does Co-Diagnostics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of CODX is sold short?

656.4K shares, 9.5% of float, as of Oct 15, 2026.

What sector is CODX in?

Healthcare, in the Surgical Instruments industry.

NASDAQ · CODXHealthcareSurgical Instruments

Co-Diagnostics, Inc. Common Stock (CODX)

$0.3614−4.89%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$0.36▼ 99.89% in range

Nov 4, 2025Low $0.35 · High $365.49Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Co-Diagnostics closed at $0.36 on Nov 4, down 4.89%, within 2.3% of its lowest close since Jul 12. Volume of 446.4K shares was 1.01× its 20-day average (close to normal).

Split-adjusted performance: -68.6% over one month.

In the quarter ended Jun 30, 2026, revenue was $166.13K, up 2.0% from a year earlier, with a net margin of -3782.4%.

Short interest was 656.4K shares at the Oct 15 settlement, up 56.7% from the prior report (9.5% of float, 1.4 days to cover).

Market cap$3.2M8.8M shares

Revenue · quarter$166.1K+2.0% YoY

Diluted EPS$-1.46—

P/E · TTM—P/S 4.4×

Net margin-3,782.4%Gross 72.7%

Dividend yieldNone

Range since Jul 120.35 – 365.49−99.9% from high

Volume446.4K1.01× 20-day avg

Volatility · 60d710.7%Annualised

Short % of float9.5%1.4 days to cover

Net cash$3.6MCash $3.6M

Next earnings—Not scheduled

Split-adjusted performance

1W −18.1%1M −68.6%3M —6M —YTD −99.8%1Y —3Y −100.0%5Y −100.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum—

Revenue growth29

Net margin3

Value (low P/E)—

Size8

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →

Shares short656.4K+56.7% vs prior

Days to cover1.4Settled Oct 15

% of float9.5%

Short vol. 10d54.7%of daily volume

Closest peers by size in Surgical Instruments

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
CODXCo-Diagnostics	$0.3614	−4.89%	—	+2.0%	−3782.4%	—	$3.2M
AMIXAutonomix Medical	$1.61	−3.01%	−80.1%	—	—	—	$3.2M	Compare
BJDXBluejay Diagnostics	$2.29	+3.62%	−69.7%	—	—	—	$2.6M	Compare
AEMDAETHLON MEDICAL	$5.75	−0.86%	−51.7%	—	—	—	$4.1M	Compare
ADGMAdagio Medical Holdings	$0.0862	0.00%	−91.1%	—	—	—	$2.4M	Compare
IVFINVO Fertility	$2.05	+5.67%	−71.7%	+16.7%	40.9%	—	$2.4M	Compare
XAIRBeyond Air	$2.33	+0.43%	−79.4%	+0.5%	−448.8%	—	$2.3M	Compare
VVOSVivos Therapeutics	$0.1112	+1.27%	−84.6%	+34.9%	−106.4%	—	$2.2M	Compare
NVNOenVVeno Medical	$7.00	−2.43%	−30.5%	—	—	—	$4.9M	Compare

News about Co-Diagnostics

All news →

Is Co-Diagnostics National Security’s Next Diagnostic Pick?Investing.com · May 28, 2026▲ Positive Co-Diagnostics Reports Full Year 2025 Financial ResultsBenzinga · Mar 31, 2026▼ Negative Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health OrganizationBenzinga · Mar 25, 2026▲ Positive

Quick answers

What does Co-Diagnostics do?: Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases.
What is CODX's market cap?: $3.19M, based on the Nov 4 close of $0.36.
Does Co-Diagnostics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of CODX is sold short?: 656.4K shares, 9.5% of float, as of Oct 15, 2026.
What sector is CODX in?: Healthcare, in the Surgical Instruments industry.

About Co-Diagnostics

Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

HQ: Salt Lake City, UT115 employeesListed Jul 12, 2017codiagnostics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology